5 Stocks Pulling The Health Care Sector Downward

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 45 points (-0.3%) at 14,466 as of Thursday, March 21, 2013, 12:44 PM ET. The NYSE advances/declines ratio sits at 1,235 issues advancing vs. 1,661 declining with 139 unchanged.

The Health Care sector currently sits down 0.1% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the sector include Pharmacyclics Incorporated ( PCYC), down 3.2%, Regeneron Pharmaceuticals ( REGN), down 2.0%, Novo Nordisk A/S ( NVO), down 1.7%, Sanofi ( SNY), down 1.3% and Alexion Pharmaceuticals ( ALXN), down 1.2%. A company within the sector that increased today was GlaxoSmithKline ( GSK), up 0.6%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5. Shire ( SHPG) is one of the companies pushing the Health Care sector lower today. As of noon trading, Shire is down $1.29 (-1.4%) to $90.80 on average volume Thus far, 235,608 shares of Shire exchanged hands as compared to its average daily volume of 329,800 shares. The stock has ranged in price between $90.23-$91.06 after having opened the day at $90.80 as compared to the previous trading day's close of $92.09.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $17.1 billion and is part of the drugs industry. The company has a P/E ratio of 23.2, above the S&P 500 P/E ratio of 17.7. Shares are down 0.2% year to date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Shire a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Shire Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

4. As of noon trading, Stryker Corporation ( SYK) is down $0.74 (-1.1%) to $64.63 on average volume Thus far, 970,854 shares of Stryker Corporation exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $64.62-$65.36 after having opened the day at $65.15 as compared to the previous trading day's close of $65.37.

Stryker Corporation, a medical technology company, provides reconstructive, medical and surgical, and neurotechnology and spine products for doctors, hospitals, and other healthcare facilities. Stryker Corporation has a market cap of $24.6 billion and is part of the health services industry. The company has a P/E ratio of 19.1, above the S&P 500 P/E ratio of 17.7. Shares are up 18.2% year to date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Stryker Corporation a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Stryker Corporation Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

3. As of noon trading, Thermo Fisher Scientific ( TMO) is down $0.63 (-0.8%) to $76.94 on heavy volume Thus far, 1.9 million shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $76.80-$77.33 after having opened the day at $77.29 as compared to the previous trading day's close of $77.57.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $27.5 billion and is part of the health services industry. The company has a P/E ratio of 22.4, above the S&P 500 P/E ratio of 17.7. Shares are up 21.4% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Thermo Fisher Scientific Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Intuitive Surgical ( ISRG) is down $3.71 (-0.8%) to $492.16 on heavy volume Thus far, 430,934 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 500,000 shares. The stock has ranged in price between $490.21-$512.00 after having opened the day at $510.00 as compared to the previous trading day's close of $495.87.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Intuitive Surgical has a market cap of $19.6 billion and is part of the health services industry. The company has a P/E ratio of 30.4, above the S&P 500 P/E ratio of 17.7. Shares are down 1.6% year to date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Intuitive Surgical a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Intuitive Surgical as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Intuitive Surgical Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Express Scripts ( ESRX) is down $0.40 (-0.7%) to $58.79 on light volume Thus far, 1.3 million shares of Express Scripts exchanged hands as compared to its average daily volume of 5.9 million shares. The stock has ranged in price between $58.56-$59.35 after having opened the day at $58.79 as compared to the previous trading day's close of $59.19.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. It offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $48.4 billion and is part of the health services industry. The company has a P/E ratio of 33.1, above the S&P 500 P/E ratio of 17.7. Shares are up 9.6% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels, increase in net income, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Express Scripts Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens